Lp(a)-associated diacylglycerols (DAGs) and lysophosphatidic acid (LPA) have a potential role in Lp(a)-induced monocyte inflammation, according to new research investigating the atherogenicity of Lp(a).
AstraZeneca has provided a sponsorship grant towards this independent programme.